Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA5 known ✓ | P31644 | 3/20 | 0.42 |
| ▸ | GABRB2 known ✓ | P47870 | 3/20 | 0.42 |
| ▸ | SLC6A1 known ✓ | P30531 | 2/20 | 0.42 |
| ▸ | GABRA1 known ✓ | P14867 | 2/20 | 0.42 |
| ▸ | GABRA4 known ✓ | P48169 | 2/20 | 0.42 |
| ▸ | MAOA known ✓ | P21397 | 1/20 | 0.37 |
| ▸ | MAOB known ✓ | P27338 | 1/20 | 0.36 |
| ▸ | GABRP known ✓ | O00591 | 1/20 | 0.35 |
| ▸ | GABRD known ✓ | O14764 | 1/20 | 0.35 |
| ▸ | GABRB1 known ✓ | P18505 | 1/20 | 0.35 |
| ▸ | GABRG2 known ✓ | P18507 | 1/20 | 0.35 |
| ▸ | GABRB3 known ✓ | P28472 | 1/20 | 0.35 |
| ▸ | GABRA3 known ✓ | P34903 | 1/20 | 0.35 |
| ▸ | GABRA2 known ✓ | P47869 | 1/20 | 0.35 |
| ▸ | GABRE known ✓ | P78334 | 1/20 | 0.35 |
| ▸ | GABRA6 known ✓ | Q16445 | 1/20 | 0.35 |
| ▸ | GABRG1 known ✓ | Q8N1C3 | 1/20 | 0.35 |
| ▸ | GABRG3 known ✓ | Q99928 | 1/20 | 0.35 |
| ▸ | GABRQ known ✓ | Q9UN88 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL473986 | 0.98 | EPHX1 (0.45) | EPHX1GNAI3GNAO1GNAI1GABRA5 | |
| Hydrochloric Acid SCHEMBL1966822 | 0.89 | SLC6A1 (0.58) | EPHX1GNAI3GNAO1GNAI1GABRA5 | |
| Hydrochloric Acid SCHEMBL1966820 | 0.89 | SLC6A1 (0.58) | EPHX1GNAI3GNAO1GNAI1GABRA5 | |
| Hydrochloric Acid SCHEMBL1970167 | 0.89 | SLC6A1 (0.58) | EPHX1GNAI3GNAO1GNAI1GABRA5 | |
| SCHEMBL15073379 | 0.87 | BRD4 (0.39) | EPHX1GNAI3GNAO1GNAI1GABRA5 | |
| SCHEMBL15054802 | 0.87 | BRD4 (0.39) | EPHX1GNAI3GNAO1GNAI1GABRA5 | |
| SCHEMBL853499 | 0.86 | SLC6A1 (0.60) | EPHX1GNAI3GNAO1GNAI1GABRA5 | |
| SCHEMBL12571547 | 0.86 | SLC6A1 (0.60) | EPHX1GNAI3GNAO1GNAI1GABRA5 | |
| SCHEMBL12571551 | 0.86 | SLC6A1 (0.60) | EPHX1GNAI3GNAO1GNAI1GABRA5 | |
| SCHEMBL8790494 | 0.85 | BRD4 (0.45) | EPHX1GNAI3GNAO1GNAI1GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118994102-A | Efluorconazole derivatives and antifungal activity thereof | 张小宇 | 2024-11-22 | — | — | CN | claimed |
| EP-3912979-B1 | TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC (US) | 2026-03-25 | — | — | EP | disclosed |
| US-20250197402-A1 | Tyrosine Kinase Inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2025-06-19 | — | — | US | disclosed |
| US-20250179032-A1 | HETEROCYCLIC INHIBITORS OF GLUT9 FOR TREATMENT OF DISEASE | HORIZON THERAPEUTICS IRELAND DAC (IE) | 2025-06-05 | — | — | US | disclosed |
| WO-2025068371-A1 | INHIBITORS OF THE PROPROTEIN CONVERTASE FURIN, METHODS OF PRODUCTION THEREOF AND USE | PHILIPPS-UNIVERSITÄT MARBURG (DE) | 2025-04-03 | — | — | WO | disclosed |
| WO-2025064788-A2 | CCR5 CONJUGATES AND USES THEREOF | CIDARA THERAPEUTICS, INC. (US) | 2025-03-27 | — | — | WO | disclosed |
| CN-118994102-A | Efluorconazole derivatives and antifungal activity thereof | 张小宇 | 2024-11-22 | — | — | CN | disclosed |
| US-20240376090-A1 | ISOXAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERED RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2024-11-14 | — | — | US | disclosed |
| EP-4460496-A1 | HETEROCYCLIC INHIBITORS OF GLUT9 FOR TREATMENT OF DISEASE | Horizon Therapeutics Ireland DAC (IE) | 2024-11-13 | — | — | EP | disclosed |
| US-20240336596-A1 | PARP7 INHIBITOR AND USE THEREOF | NOVOSTAR PHARMACEUTICALS, LTD. (CN) | 2024-10-10 | — | — | US | disclosed |
| US-5958952-A | CONTROLLING AGGREGATION OF CELLS; ANTITUMOR AGENT | DR. KARL THOMAE GMBH (DE) | 1999-09-28 | — | — | US | disclosed |
| US-5922717-A | ANTICOAGULANTS | DR. KARL THOMAE GMBH (DE) | 1999-07-13 | — | — | US | disclosed |
| CN-1183770-A | Piperazine derivatives, medicaments containing these compounds, their use and processes for their preparation | THOMAE GMBH DR K (DE) | 1998-06-03 | — | — | CN | disclosed |
| EP-0815103-A1 | TRYPSIN AND THROMBIN INHIBITORS | Novartis AG (CH) | 1998-01-07 | — | — | EP | disclosed |
| US-5700801-A | ANTIINFLAMMATORY AGENTS, BONE DISORDERS | KARL THOMAE, GMBH (DE) | 1997-12-23 | — | — | US | disclosed |
| US-5563268-A | FOR PREVENTING CELL AGGLOMERATION, TREATING THROMBOSIS, ARTERIOSCLEROSIS, BRAIN, LUNG OR CARDIOVASCULAR DISORDERS | DR. KARL THOMAE GMBH (DE) | 1996-10-08 | — | — | US | disclosed |
| WO-1996029327-A1 | TRYPSIN AND THROMBIN INHIBITORS | NOVARTIS AG (CH) | 1996-09-26 | — | — | WO | disclosed |
| US-5442064-A | Anticoagulants, antiagglomerants | DR. KARL THOMAE GMBH (DE) | 1995-08-15 | — | — | US | disclosed |
| US-5418233-A | FOR INHIBITING CELL AGGREGATION | KARL THOMAE GMBH (DE) | 1995-05-23 | — | — | US | disclosed |
| CN-1087904-A | Carboxylic acid derivative, the pharmaceutical composition that contains these compounds with and preparation method thereof | KRAL THOMAE GMBH (DE) | 1994-06-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240376090-A1 | ISOXAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERED RELATED THERETO | HTR2A, HTR5A, HTR1A | GABRA5 40/4885GABRB2 59/4885SLC6A1 36/4885 |
| US-20250179032-A1 | HETEROCYCLIC INHIBITORS OF GLUT9 FOR TREATMENT OF DISEASE | SLC2A9, SLC2A1, SLC2A8 | GABRA5 1983/4885GABRB2 1422/4885SLC6A1 483/4885 |
| US-20240336596-A1 | PARP7 INHIBITOR AND USE THEREOF | PARP1, PARP3, PARP11 | GABRA5 3390/4885GABRB2 4035/4885SLC6A1 3694/4885 |
| US-20250197402-A1 | Tyrosine Kinase Inhibitors | BTK, LYN, SYK | GABRA5 3620/4885GABRB2 3189/4885SLC6A1 4796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.